Merck suffers setback over new Keytruda formulation in Germany

What's new in pharma

December 5, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Merck suffers a setback over its new Keytruda formulation in Germany The ruling is the latest in the battle between Merck and Halozyme that is playing out on both sides of the Atlantic By Ed Silverman CDC panel recommends delaying birth dose of hepatitis B vaccine ACIP recommends delaying when babies are vaccinated against hepatitis B, overturning a 30-year-old policy that contributed to a massive decline in cases. By Helen Branswell STAT+ | In sweeping presentation, vaccine critic urges government advisers to rethink childhood shots Siri, an attorney with close ties to RFK, led the committee through a 76-slide presentation on the childhood vaccine schedule. By Daniel Payne Adobe STAT+ | Opinion: Sandoz chief scientific officer: What is truly necessary to establish biosimilarity? Extensive biosimilar comparative efficacy trials add little scientific value while increasing costs and delaying patient access, Sandoz CSO writes. By Claire D'Abreu-Hayling STAT+ | Cancer detection firm Freenome to go public via $330 million SPAC deal Freenome will hit the public markets by merging with Perceptive Capital Solutions Corp, a SPAC, in a $330 million deal. By Jonathan Wosen STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser